Japanese encephalitis (JE) is a mosquito-borne virus that affects the central nervous system and is a major cause of mortality and morbidity in many parts of the world. It is estimated that there are around 68,000 cases of JE each year, resulting in around 10,000 deaths. Although the disease has been known to exist for centuries, the exact cause of the disease and its transmission remain largely unknown. This article will explore the current state of knowledge about JE, the challenges faced in controlling it, and the potential strategies for addressing this global health challenge.
Japanese encephalitis is a viral infection of the central nervous system caused by the Japanese encephalitis virus (JEV). It is a member of the Flaviviridae family, which also includes the West Nile virus, yellow fever virus, and dengue virus. JEV is transmitted to humans through the bite of an infected mosquito, usually of the genus Culex. The virus is endemic in many parts of Asia, including India, China, Japan, Korea, and Southeast Asia. The symptoms of JE can range from mild to severe, depending on the individual's age and immune status. In mild cases, symptoms may include fever, headache, nausea, and vomiting. In more severe cases, the virus can cause inflammation of the brain, leading to seizures, paralysis, and even death.
The epidemiology of JE is complex and not fully understood. It is estimated that there are around 68,000 cases of JE worldwide each year, resulting in around 10,000 deaths. The highest incidence of JE is seen in rural areas of Asia, particularly in India, China, Japan, and Southeast Asia. The transmission of JE is closely linked to the ecology of the mosquito vector. The virus is most commonly transmitted during the rainy season when the number of mosquitoes is highest. The virus is also spread through the migration of infected birds, which can serve as a reservoir for the virus.
The diagnosis of JE is based on clinical symptoms as well as laboratory testing. The most commonly used laboratory test is the enzyme-linked immunosorbent assay (ELISA), which detects the presence of antibodies to the JEV. Other tests, such as polymerase chain reaction (PCR), can also be used to detect the virus itself. There is no specific treatment for JE, and management is largely supportive. The mainstay of treatment is supportive care, including the use of antipyretics, analgesics, and anticonvulsants. In severe cases, intensive care may be necessary.
The best way to prevent JE is to reduce the risk of mosquito bites. This can be done by using insect repellents, wearing long-sleeved clothing, and avoiding areas where mosquitoes are known to be present. Vaccination is the most effective way to protect against JE. Currently, there are two types of JE vaccines available: an inactivated vaccine and a live attenuated vaccine. The inactivated vaccine is recommended for adults and children over the age of two months, while the live attenuated vaccine is recommended for children under the age of two months. In addition to vaccination, vector control measures, such as the use of insecticides and larvicides, can also be used to reduce the risk of transmission.
Japanese encephalitis is a mosquito-borne virus that affects the central nervous system and is a major cause of mortality and morbidity in many parts of the world. Despite its long history, the exact cause of the disease and its transmission remain largely unknown. The best way to prevent JE is through vaccination and vector control measures, such as the use of insecticides and larvicides. There is no specific treatment for JE, and management is largely supportive.
1.
Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca
2.
More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer
3.
Asymptomatic Brain Metastases in EGFR-Mutant NSCLC
4.
Mapping lifelong chronic health risks for childhood cancer survivors
5.
Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC
1.
Respiratory Ramifications of Systemic Disease: A Comprehensive Review
2.
Revolutionizing Lung Cancer Treatment: Exploring the Benefits of Wedge Resection Surgery
3.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
4.
Cancer Care Advances: Metformin, Digital Tools, and Artificial Renal Support
5.
Molecular Mechanisms, Clinical Efficacy, and Stem Cell Therapy Integration in Leukemia Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation